8-K: Atossa Therapeutics Announces Positive Phase 2 Results and Provides Corporate Update

Atossa Therapeutics reported positive results from a Phase 2 study of (Z)-endoxifen, showing significant reductions in mammographic breast density, and provided a corporate update including financial results for the third quarter of 2024.

Summary

• Atossa Therapeutics announced its third quarter 2024 financial results and provided a corporate update.
• The company reported positive topline results from the KARISMA-Endoxifen Phase 2 study, which showed significant reductions in mammographic breast density (MBD) with low doses of (Z)-endoxifen.
• The study demonstrated a 19.3% reduction in MBD in the 1mg treatment arm and a 26.5% reduction in the 2mg treatment arm compared to placebo over a six-month period.
• A preliminary analysis from the I-SPY 2 Endocrine Optimization Pilot (EOP) Phase 2 trial of (Z)-endoxifen met its primary endpoint, with 95% of patients completing over 75% of the planned treatment.
• This trial also showed a 69% reduction in Ki-67 and a 30.4% reduction in functional tumor volume after three weeks.
• Atossa initiated a clinical trial in partnership with Quantum Leap Healthcare Collaborative, evaluating (Z)-endoxifen in combination with abemaciclib (VERZENIO).
• The company received a new U.S. patent covering certain compositions of (Z)-endoxifen.
• Atossa ended the third quarter of 2024 with $74.8 million in cash and cash equivalents and no debt.
• Total operating expenses for the quarter were $6.4 million, a decrease of $1.1 million compared to the same period in 2023.
• The company reported a net loss of $7.2 million for the quarter and $19.2 million for the nine months ended September 30, 2024.

Sentiment

Score: 8

Explanation: The document presents very positive clinical trial results and a strong cash position, which are favorable for investors. However, the company is still operating at a loss, which tempers the overall sentiment slightly.

Positives

• The KARISMA-Endoxifen Phase 2 study demonstrated significant reductions in mammographic breast density, a key risk factor for breast cancer.
• The I-SPY 2 EOP trial showed promising results with a high percentage of patients completing treatment and rapid reductions in key breast cancer biomarkers.
• The combination trial with abemaciclib represents a potential new treatment approach for high-risk breast cancer patients.
• The new patent strengthens Atossa's intellectual property position for (Z)-endoxifen.
• The company has a strong cash position with $74.8 million and no debt.
• Operating expenses have decreased compared to the prior year periods.

Negatives

• The company reported a net loss of $7.2 million for the quarter and $19.2 million for the nine months ended September 30, 2024.
• Interest income decreased by $0.3 million for the quarter due to a decrease in funds invested in the money market account.
• The company recorded an impairment charge of $1.7 million on its investment in equity securities for the nine months ended September 30, 2024.
• General and administrative professional fees increased by $0.3 million for the quarter and $1.9 million for the nine months ended September 30, 2024, primarily due to higher legal and investor relations expenses.

Risks

• The company's forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially.
• These risks include macroeconomic conditions, regulatory approvals, the success of clinical trials, and the ability to raise capital.
• There is a risk of variation between interim and final clinical results.
• The company's ability to successfully develop and commercialize new therapeutics is not guaranteed.
• The company's ability to remain compliant with Nasdaq listing requirements is a risk.

Future Outlook

The company anticipates results from the combination trial with abemaciclib in 2026 and will continue to advance its (Z)-endoxifen program. They also plan to continue to develop innovative therapies that can meaningfully impact breast cancer treatment and prevention.

Management Comments

• Steven Quay, M.D., Ph.D., Atossa's President and Chief Executive Officer, stated that the positive results from the KARISMA-Endoxifen Phase 2 study and the promising data from the I-SPY 2 EOP trial further validate the substantial potential of their programs.
• Management believes these results demonstrate their commitment to developing innovative therapies that can meaningfully impact breast cancer treatment and prevention.

Industry Context

This announcement is significant in the context of breast cancer treatment and prevention, as it highlights the potential of (Z)-endoxifen as a preventative therapy for women with dense breast tissue and as a treatment for ER+/HER2breast cancer. The combination trial with abemaciclib also aligns with the industry trend of exploring combination therapies to improve patient outcomes.

Comparison to Industry Standards

• The reported 19.3% and 26.5% reduction in MBD in the KARISMA-Endoxifen study are promising compared to other breast density reduction agents, such as tamoxifen, which has shown variable results.
• The 95% treatment completion rate in the I-SPY 2 EOP trial is high, indicating good tolerability of (Z)-endoxifen, which is a positive sign compared to other cancer treatments that often have high discontinuation rates due to side effects.
• The 69% reduction in Ki-67 and 30.4% reduction in tumor volume in the I-SPY 2 EOP trial are also notable, as Ki-67 is a key biomarker for tumor proliferation and these results are comparable to or better than some other endocrine therapies.
• The combination of (Z)-endoxifen with abemaciclib is a novel approach, as abemaciclib is a CDK4/6 inhibitor, and this combination could potentially offer a more effective treatment option for ER+/HER2breast cancer compared to single-agent therapies.

Management Changes

Stakeholder Impact

• Shareholders will likely view the positive clinical trial results and strong cash position favorably.
• Employees may be encouraged by the company's progress and growth.
• Patients with breast cancer may benefit from the development of new treatment options.
• The company's suppliers and partners may see increased business opportunities.

Next Steps

• The company will continue to enroll patients in the combination trial with abemaciclib.
• Atossa will continue to advance its (Z)-endoxifen program in various Phase 2 trials.
• The company will continue to seek regulatory approvals for its (Z)-endoxifen program.
• Atossa will continue to develop innovative therapies for breast cancer.

Key Dates

Keywords

Atossa Therapeutics, Z-endoxifen, breast cancer, mammographic breast density, clinical trials, KARISMA-Endoxifen, I-SPY 2, abemaciclib, patent, biopharmaceutical, oncology